Corcept Therapeutics (CORT) Competitors $55.31 +0.87 (+1.60%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CORT vs. RPRX, JAZZ, PRGO, SUPN, PCRX, OMER, NKTR, ASMB, CPIX, and LLYShould you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry. Corcept Therapeutics vs. Royalty Pharma Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Omeros Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Corcept Therapeutics (NASDAQ:CORT) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Does the MarketBeat Community favor CORT or RPRX? Corcept Therapeutics received 214 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 71.16% of users gave Corcept Therapeutics an outperform vote while only 67.92% of users gave Royalty Pharma an outperform vote. CompanyUnderperformOutperformCorcept TherapeuticsOutperform Votes53871.16% Underperform Votes21828.84% Royalty PharmaOutperform Votes32467.92% Underperform Votes15332.08% Does the media prefer CORT or RPRX? In the previous week, Royalty Pharma had 6 more articles in the media than Corcept Therapeutics. MarketBeat recorded 11 mentions for Royalty Pharma and 5 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 1.00 beat Royalty Pharma's score of 0.88 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Royalty Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, CORT or RPRX? Corcept Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Do insiders and institutionals believe in CORT or RPRX? 93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 20.5% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 18.9% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer CORT or RPRX? Corcept Therapeutics presently has a consensus target price of $65.25, indicating a potential upside of 17.97%. Royalty Pharma has a consensus target price of $41.67, indicating a potential upside of 35.50%. Given Royalty Pharma's higher possible upside, analysts clearly believe Royalty Pharma is more favorable than Corcept Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Royalty Pharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is CORT or RPRX more profitable? Royalty Pharma has a net margin of 50.53% compared to Corcept Therapeutics' net margin of 22.35%. Royalty Pharma's return on equity of 24.65% beat Corcept Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Corcept Therapeutics22.35% 24.54% 20.24% Royalty Pharma 50.53%24.65%14.44% Which has stronger earnings & valuation, CORT or RPRX? Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorcept Therapeutics$482.38M12.01$106.14M$1.2643.90Royalty Pharma$2.27B8.00$1.13B$1.9315.93 SummaryCorcept Therapeutics beats Royalty Pharma on 9 of the 17 factors compared between the two stocks. Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORT vs. The Competition Export to ExcelMetricCorcept TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.80B$6.58B$5.35B$9.06BDividend YieldN/A2.94%5.13%4.02%P/E Ratio43.909.8389.4817.34Price / Sales12.01307.731,251.60134.53Price / Cash52.0561.4443.7535.97Price / Book11.246.055.324.80Net Income$106.14M$154.62M$122.60M$224.91M7 Day Performance10.95%-1.70%0.88%1.90%1 Month Performance5.51%2.75%4.81%5.08%1 Year Performance123.57%2.60%27.90%21.15% Corcept Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORTCorcept Therapeutics4.5451 of 5 stars$55.31+1.6%$65.25+18.0%+122.8%$5.22B$482.38M43.90300Insider TradeRPRXRoyalty Pharma4.7806 of 5 stars$30.45+3.3%$41.67+36.8%+8.5%$17.94B$2.27B15.7880Dividend IncreaseOptions VolumeJAZZJazz Pharmaceuticals4.9855 of 5 stars$123.50+1.7%$177.00+43.3%+2.9%$7.47B$3.99B17.393,200Short Interest ↓News CoveragePRGOPerrigo4.9426 of 5 stars$24.43+0.2%$35.00+43.3%-27.1%$3.33B$4.39B-20.889,140Analyst DowngradeOptions VolumeSUPNSupernus Pharmaceuticals3.7282 of 5 stars$37.81+0.9%$46.50+23.0%+35.2%$2.09B$651.97M35.34580News CoveragePCRXPacira BioSciences2.5845 of 5 stars$21.69+5.1%$24.30+12.0%-29.3%$1.00B$694.96M-10.68720Analyst ForecastAnalyst RevisionNews CoverageOMEROmeros4.2441 of 5 stars$8.59-2.8%$22.50+161.9%+140.5%$497.79MN/A-3.72210Analyst ForecastNews CoveragePositive NewsGap DownNKTRNektar Therapeutics4.4201 of 5 stars$0.97-6.1%$4.08+322.0%+80.7%$178.46M$93.14M-1.15220ASMBAssembly Biosciences3.9961 of 5 stars$15.10-3.3%$35.00+131.8%+47.3%$95.98M$28.33M0.00100Positive NewsCPIXCumberland Pharmaceuticals0.7875 of 5 stars$2.32-0.4%N/A+28.4%$32.58M$36.79M-3.0180Positive NewsLLYEli Lilly and Company4.9958 of 5 stars$802.69+0.3%$1,002.22+24.9%+15.5%$762.01B$40.86B86.7839,000Analyst RevisionNews Coverage Related Companies and Tools Related Companies Royalty Pharma Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Omeros Competitors Nektar Therapeutics Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CORT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
